Synapse - Bayard Clarkson

Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells

Journal Article

Liang, X.; Hajivandi, M.; Veach, D.; Wisniewski, D.; Clarkson, B.; Resh, M. D.; Pope, R. M.
Proteomics (2006)

Fulltext@MSK | Save

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

Journal Article

Azam, M.; Nardi, V.; Shakespeare, W. C.; Metcalf, C. A. 3rd; Bohacek, R. S.; Wang, Y.; Sundaramoorthi, R.; Sliz, P.; Veach, D. R.; Bornmann, W. G.; more...
Proceedings of the National Academy of Sciences of the United States of America (2006)

Fulltext@MSK | Save

C-elegans ABL-1 functions similarly to Bcr-Abl and antagonizes p53-mediated germ cell apoptosis

Meeting Abstract

Deng, X.; Yin, X.; Veach, D. R.; Clarkson, B.; Bornmann, W. G.; Fuks, Z.; Kolesnick, R. N.
Cancer Research (2005)

Fulltext@MSK | Save

BCR-ABL kinase dynamics in drug resistance

Meeting Abstract

Azam, M.; Nardi, V.; Shakespeare, W.; Latek, R. R.; Bohacek, R.; Veach, D.; Clarkson, B.; Sawyer, T. K.; Daley, G. Q.
Clinical Cancer Research (2005)

Fulltext@MSK | Save

BCR-ABL kinase dynamics and drug resistance

Meeting Abstract

Azam, M.; Nardi, V.; Shakespear, W. C.; Latek, R. R.; Veach, D.; Clarkson, B.; Bohacheck, R.; Sawyer, T. K.; Daley, G. Q.
Blood (2005)

Fulltext@MSK | Save

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

Journal Article

Wolff, N. C.; Veach, D. R.; Tong, W. P.; Bornmann, W. G.; Clarkson, B.; Ilaria, R. L.
Blood (2005)

Fulltext@MSK | Save